The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What patients benefit most from the addition of venetoclax to FLAG-IDA?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked, What patients benefit most from the addition of venetoclax to FLAG-IDA?

What patients benefit most from the addition of venetoclax to FLAG-IDA?

In this video, Lachowiez gives an overview of the studies evaluating the addition of venetoclax to cytotoxic agents.

 

Share: